Loading
American surgeon who pioneered removing the thyroid in children with inherited RET mutations before cancer develops, led ZETA, the trial that established vandetanib for medullary thyroid cancer, and chaired the American Thyroid Association guideline for the disease.
Samuel Wells Jr. is an endocrine surgeon whose career spanned Duke University, Washington University in St Louis and the National Cancer Institute. He showed that prophylactic thyroidectomy guided by RET mutation testing prevents medullary thyroid cancer in multiple endocrine neoplasia type 2. He was first author of the 2012 Journal of Clinical Oncology report of ZETA, the phase 3 trial in which vandetanib lengthened progression-free survival in advanced medullary thyroid cancer, the first drug approved for the disease, and chaired the 2015 American Thyroid Association guideline.
| Title | Journal | Year |
|---|---|---|
| Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma | Thyroid | 2015 |
| ZETA: vandetanib in locally advanced or metastatic medullary thyroid cancer | Journal of Clinical Oncology | 2012 |
The medullary thyroid cancer page's approach to hereditary carriers and to surgery without radioactive iodine follows this guideline.
Vandetanib is an approved option for progressive medullary thyroid cancer, used less since selpercatinib for RET-mutant disease.
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, trialist.
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, trialist.
Shares Medullary thyroid cancer, Thyroid cancer and the tags thyroid, trialist.
Shares ZETA: vandetanib in locally advanced or metastatic medullary thyroid cancer, ZETA, Medullary thyroid cancer, Thyroid cancer.
Shares the tags surgery, trialist.
Shares the tags surgery, trialist.
Shares the tags surgery, trialist.
Shares the tags surgery, trialist.